156 related articles for article (PubMed ID: 25960412)
21. Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):28-34. PubMed ID: 26754263
[TBL] [Abstract][Full Text] [Related]
22. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
23. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
[TBL] [Abstract][Full Text] [Related]
24. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Alvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Ayala-Gil A; Fernández-Gonzalo P; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Lara PC
PLoS One; 2013; 8(7):e69735. PubMed ID: 23936089
[TBL] [Abstract][Full Text] [Related]
26. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
27. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Tong M; Jin YY; Li G; Liu SM; Ji CD
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
[TBL] [Abstract][Full Text] [Related]
28. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
29. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
[TBL] [Abstract][Full Text] [Related]
31. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease.
Signorelli SS; Barresi V; Musso N; Anzaldi M; Croce E; Fiore V; Condorelli DF
J Endocrinol Invest; 2008 Dec; 31(12):1092-7. PubMed ID: 19246976
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Akalu A; Dlmajian DA; Highshaw RA; Nichols PW; Reichardt JK
J Urol; 1999 Apr; 161(4):1355-8. PubMed ID: 10081907
[TBL] [Abstract][Full Text] [Related]
34. Association of genetic variants in the two isoforms of 5α-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
Graupp M; Wehr E; Schweighofer N; Pieber TR; Obermayer-Pietsch B
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):175-9. PubMed ID: 21530059
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms and prostate cancer risk.
Gsur A; Feik E; Madersbacher S
World J Urol; 2004 Feb; 21(6):414-23. PubMed ID: 14648103
[TBL] [Abstract][Full Text] [Related]
37. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
38. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Robitaille CN; Rivest P; Sanderson JT
Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
[TBL] [Abstract][Full Text] [Related]
39. Inherited variation in hormone-regulating genes and prostate cancer survival.
Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
[TBL] [Abstract][Full Text] [Related]
40. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
